Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Novartis hikes profit guidance again after stellar Q2
(Sharecast News) - Swiss pharma titan Novartis has raised its full-year profit guidance for the second time in three months after strong sales growth and margin expansion in its second quarter. The company is now guiding to mid to high teens growth in core operating income in 2024, up from April's guidance of low double-digit to mid-teens growth. Prior to April, guidance had been for high single-digit growth.
"Our performance reflects continued strong momentum of our key growth drivers, both in the US and ex-US, which has allowed us to upgrade our FY2024 guidance," said chief executive Vas Narasimhan.
Net sales in the second quarter were up 11% on last year at constant currencies at $12.51bn, despite generic competition and pricing both having a 2 percentage-point negative impact on top line growth each.
Sales of the company's biggest-selling products, heart medication Entresto, psoriasis and arthritis treatment Cosentyx and multiple sclerosis drug Kesimpta, all came in ahead of what analysts were expecting.
Entresto sales rose 28% increase to $1.90bn, helped by increased penetration in the US and Europe, along with China; Cosentyx sales gained 22% to $1.53bn; while Kesimpta sales jumped 65% to $799m.
Headline operating income was up 47% on last year at $4.01bn, while adjusted or core operating income rose 19% to $4.95bn, smashing the $4.6bn expected by the market. The core operating income margin jumped 270 basis points to 39.6%.
Free cash flow surged 40% in US dollar terms to $4.6bn, helped by higher net cash flows from operating activities.
Despite the strong results, the stock was down 2.1% at CHF96.96 by 1030 in Zurich.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.